Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) on Monday announced the publication of Phase 2 SARA-INT trial results for BIO101 in the Journal of Cachexia, Sarcopenia and Muscle.
The findings confirm the company's readiness to advance to Phase 3 in the development of a potential treatment for sarcopenia.
BIO101 demonstrated a clinically meaningful improvement in the 400-metre walk test, the study's primary endpoint, and showed a strong safety profile with no serious adverse events. The treatment was particularly effective in high-risk populations, including slow walkers and patients with sarcopenic obesity.
With no approved therapeutic solutions for sarcopenia, which affects up to 194 million people globally, Biophytis remains at the forefront of innovation in this field. The company is making regulatory progress for Phase 3 trials and is in active discussions with a major pharmaceutical partner in China and other industrial collaborators in Asia.
ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi's efdoralprin alfa shows superior results in phase 2 study for AATD
Genflow Biosciences publishes second European patent application for SIRT6 Variant in NASH
Trellus Health signs contract with leading global CRO and expands clinical trial offerings
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity
The Los Angeles Trust for Children's Health Appoints Dr Sarah Rodman as New Executive Director
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
ACG to invest USD200m in US hard-shell capsule manufacturing